Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Study of Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP
2018-003430-33Phase 4
- Sponsor
- CSL Limited
- Start
- Sep 2018
- Countries
- 1
01
Overview
Phase 4, randomised trial of polyvalent human immunoglobulin in chronic inflammatory demyelinating polyneuropathy (CIDP) (2 arms), sponsored by CSL Limited. Primary endpoint: CIDP relapse during randomized phase.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on 2018-003430-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003430-33.